472 related articles for article (PubMed ID: 19016726)
1. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
[TBL] [Abstract][Full Text] [Related]
2. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
4. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
5. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
8. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
10. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
11. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
14. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
16. Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006.
Thörn I; Forestier E; Thuresson B; Wasslavik C; Malec M; Li A; Lindström-Eriksson E; Botling J; Barbany G; Jacobsson S; Olofsson T; Porwit A; Sundström C; Rosenquist R
Eur J Haematol; 2010 Feb; 84(2):117-27. PubMed ID: 19895569
[TBL] [Abstract][Full Text] [Related]
17. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
18. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
20. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Lönnerholm G; Thörn I; Sundström C; Frost BM; Abrahamsson J; Behrendtz M; Heldrup J; Jacobsson S; Li A; Olofsson T; Porwit A; Söderhäll S; Larsson R; Forestier E
Leuk Res; 2009 Jan; 33(1):46-53. PubMed ID: 18639340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]